Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here we go!
IPA is looking great. CEO is meeting with investors this week and presenting at LD Micro on Friday. I believe we’ll be seeing a lot of news going forward as they will be uplisting to Nasdaq in near future. Warrants are providing a little selling pressure - if it wasn’t for the warrants we’d be a lot higher. Really excited for the next month and post Nasdaq listing.
It was a great presentation. After listening to Jennifer I’m confident that they’ll get some federal funding from DARPA/BARDA. In talks with 6-7 large pharmas for out licensing deals. Sounds like they’ll be taking their Polytope therapy as far as possible before a likely partnership with big pharma. That will be the biggest deal.
https://www.natesessentials.com
https://www.natesessentials.com/termsandconditions
Nate’s Essentials is a wholly owned subsidiary of Nate's Foods Co. Inc. (the “Company”)
A big pharma partnership has to be coming soon. IPA has such a massive Covid mAb library and with already having relationships with many pharmas for their CRO business, I’d expect at least one of them to get involved.
Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA's Proprietary B cell Select™ and Single Step Cloning Hybridoma Technologies
https://www.newswire.ca/news-releases/functional-human-antibodies-targeting-sars-cov-2-discovered-using-ipa-s-proprietary-b-cell-select-tm-and-single-step-cloning-hybridoma-technologies-855898620.html
https://www.talemtherapeutics.com/pipeline
They got into a research license agreement with Janssen (Johnson&Johnson) in April for an undisclosed target. Most likely for a type of cancer.
They recently announced several neutralizing SARS-cov-2 antibodies from their human and llama campaign. They will be soon announcing their antibodies discovered on Ligand’s (LGND) OmniAb platform (OmniRat) and also Rabbit antibodies. They’ll have 1600 Covid neutralizing mAbs.
In 2019 they created Talem Therapeutics which gives them the ability to out license their antibodies and partner with Big Pharma or whoever wants them. They already do business with several of big pharmas so the connections and trust are already there. When companies want to use IPAs services the audit process is roughly a year long so the Big Pharmas that are already on board should be very interested in their Covid discoveries.
They collaborated with the NIH for characterization of their antibodies. That should be released in a peer reviewed article in the near future. That will be big news and provide validation to the companies interested in licensing with them.
I don’t think there’s another company with the amount of sars-cov-2 specific antibodies like IPA. They did everything from the ground up and discovered mAbs from Humans, Llamas, Rabbits and OmniRat.
Will be interesting to see what moves they make this summer. They have potential to do several licensing deals (upfront payment+royalties) and also take an antibody cocktail through animal trials themselves.
IPA is also developing a saliva based test with the University of Victoria. A photographer from Bloomberg was there the other day so we should see some media coverage soon.
They also announced a Covid vaccine program that’s being funded by TRANSVAC in Europe. You only get that if your antibodies are good.
There’s so much going on with this company right now so we should be getting a lot of news soon. I’m sure their strategy is to bring in as many licensing deals (upfront payments) as possible which will set them up for future projects in immuno-oncology.
Few more developments and we should be headed to the Nasdaq where the real fun will start.
Nice to have another person on the board.
Hard to believe how undiscovered this still is. Great news released on Monday although
current investors expected that type of news so wasn’t much of a surprise. Results from Ligand platform should be out soon and I hope Ligand does a PR on IPAs discoveries using their platform. A lot of things happening with this company and I feel like we’ll have a big licensing deal happen this month.
Ya let’s get a company update here. Even a name change would be a start haha
IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2
Source: PR Newswire (Canada)
IPA Announces Discovery of Functional Antibodies from Humans and Llama (VHH), Identified Using IPA Phage Display Technology
VICTORIA, BC, June 29, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), an experienced leader in full-service, therapeutic antibody discovery and development, today announced the identification of numerous lead candidate antibodies with highly-potent neutralizing activity in vitro, which are being manufactured for further testing and possible inclusion in the Company's PolyTopeTM mAb Therapy to combat the COVID-19 pandemic.
ImmunoPrecise Antibodies Ltd. Logo (CNW Group/ImmunoPrecise Antibodies Ltd.)
On March 12th, 2020, ImmunoPrecise announced several preclinical programs currently being undertaken to assist in the efforts against SARS-CoV-2. Today's announcement updates the Company's progress on the development of a PolyTope™ mAb therapy designed to treat severely ill patients, as well as protect high-risk individuals such as those exposed to the virus, front-line workers, the elderly, and the immunocompromised.
ImmunoPrecise deployed several proprietary discovery platforms that leveraged the immune systems of humans, llama, rabbits and Ligand Pharmaceutical's (NASDAQ:LGND) OmniAbÒ genetically engineered rats producing human antibodies. The neutralizing antibodies announced today are the result of functional screenings from the top 300 lead antibodies analyzed from the human and llama campaigns. The Company has stated that functional analysis of the remaining 1,300 lead antibodies from the rabbit and OmniAbÒ rat campaigns were performed independently, and they anticipate the release of the preliminary functional data screens from these additional programs in the near future.
"Arriving at this critical point in our preliminary research with many lead, functional therapeutic candidates is indicative of the broad scientific scope of IPA's anti-COVID-19 programs," stated Dr. Jennifer Bath, CEO and President of IPA. "An effective cocktail therapy for COVID-19, targeting multiple epitopes on the virus, could prove fundamental in combating this pandemic in an effective and enduring way."
The Company's scientific approach has led to a diverse set of lead antibody candidates, and thus far has generated many potently neutralizing antibodies to multiple epitopes, supporting the Company's aim of generating a therapeutic that retains efficacy, even as SARS-CoV-2 continues to evolve. To further support the Company's robust scientific approach, IPA is preparing to test these lead antibodies against additional, documented, mutated strains of the virus.
The Company anticipates pre-clinical studies will begin summer 2020.
Jennifer Bath, Ph.D., Chief Executive Officer of ImmunoPrecise, has reviewed and approved the scientific disclosure of this news release.
The use of therapeutics for humans in clinical trials will require approval of the applicable government regulation agency, e.g. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or SARS-CoV-2) at this time.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com.
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend" and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, ImmunoPrecise may not be successful in the development of any vaccine, therapy or diagnostic kits to be used in the prevention, treatment or diagnosis of SARS-CoV-2, actual revenues and earnings for IPA being lower than anticipated, potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions and disruption of the global economy, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the previous quarter ended January 31, 2020 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ImmunoPrecise Antibodies
News out!
Exciting stuff! Should be lots of news the next month. Antibody characteristics and then hopefully followed by some big licensing deals.
Ya I was thinking it could take longer than we think. $VIR announced a collaboration with NIH in March for antibody characteristics and they announced their results mid May. I don’t think it will take another month with IPA but maybe another week or two. Hoping for some great results followed by 1 or more big licensing deals. Tons of money going into Covid treatment companies so IPA could see some explosive movement soon.
Back up we go. Should be seeing functional data any day now. I believe that’s when the fun will start.
Weird that 8k hasn’t showed up on IHub
Would love to see what he said. Hoping for name change and news soon!
Collaborative COVID-19 Vaccine Project Between ImmunoPrecise Antibodies Europe and LiteVax BV, Funded Through TRANSVAC2
https://www.newswire.ca/news-releases/collaborative-covid-19-vaccine-project-between-immunoprecise-antibodies-europe-and-litevax-bv-funded-through-transvac2-838918671.html
Exciting times ahead here. After they release peer reviewed antibody data and maybe a partnership we should see IPATF over $4.00. They can then think about uplisting to NASDAQ which would be huge for investors.
I would expect a name and ticker symbol change soon. Not sure what the hold up is. I’m sure they’d like to announce news under their new name.
Sorry they’re not. Just showing proof that there’s going to be a big market for vertical take off technology. I hope the company will release news soon on their plans going forward.
Vertical takeoff jet company worth a billion dollars.
https://lilium.com
If they partner up with JNJ or some other big pharma then this will go way passed $4.00. Especially in this crazy market right now. One step at a time though. Release the antibody data to the public and then hopefully partner up with someone to develop a antibody cocktail.
They should be releasing a peer reviewed article soon on their neutralizing antibodies. I’m sure they’ll soon partner up with big pharma. Could end up being Janssen due to their previously announced agreement. Exciting times ahead.
Strong volume here today on the US side. Nice to see more US investors making the IPA discovery. This company is still a secret and will be worth a whole lot more once antibody news and partnerships come out.
Let’s see some antibody data next week!
That was obvious with the amount of preferred shares. Those can’t be converted immediately to common shares though due to regulations
Name will be changed to Xeriant
https://xeriant.com/
What’s going on here today?
Would love to know more about how the technology works. Using your phone camera to detect Covid antibodies in your saliva would obviously be extremely valuable. Getting data immediately would allow governments to manage the virus better.
Didn’t expect test kit news! A test that’s done with a phone and saliva would be a game changer in managing the virus. No idea how the technology works and how accurate it is but could be very valuable. They also said this is just one portion of their coronavirus program. This is a good start!
Talem Therapeutics, has entered into a research license agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen"), providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target. Pursuant to the Agreement, Janssen holds an option to acquire all commercial rights to the antibodies.
Yes it would be a great partnership and would also show everyone that IPA is the real deal and on their way to becoming a billion dollar biotech.
Liking where this is right now. Let’s get some positive antibody data and Big Pharma will be knocking at their door.
Other biotechs involved in antibody treatment have had market caps increase by US$1 Billion with positive news. Sounds like it would be too good to be true for ImmunoPrecise to be worth that much but if they have a strong Covid mAb library, why not?
You have an idea where they are in terms of research? They’ve been focusing on Covid for months now. They must be very close to announcing details about their discoveries. Hoping that partnership with Janssen leads to a large deal too.